New drug combo targets breathing pauses in sleep apnea
NCT ID NCT06776432
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times
Summary
This Phase 2A study tests three drugs—sivopixant, acetazolamide, and SASS-001—in 60 adults with sleep apnea that has a central component (where the brain fails to signal breathing). The goal is to see if these drugs can reduce the number of breathing pauses during sleep. Participants have conditions like heart failure or atrial fibrillation. The study compares each drug against a placebo to measure safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLEEP APNEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California, 92037, United States
-
Huntsville Research Institute LLC
Huntsville, Texas, 77340, United States
-
Infinity Medical Research
North Dartmouth, Massachusetts, 02747, United States
-
Intrepid Research, LLC
Cincinnati, Ohio, 45245, United States
-
John D. Dingell VA Medical Center
Detroit, Michigan, 48201, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
OnSite Clinical Solutions
Rock Hill, South Carolina, 29732, United States
-
PharmaDev Clinical Research Institute, LLC
Miami, Florida, 33176, United States
-
Teradan Clinical Trials
Brandon, Florida, 33511, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sivopixant, acetazolamide, and SASS-001 (drugs)
What this could lead to
If successful, this could point toward new medication options to reduce breathing pauses during sleep for people with central sleep apnea.
What could go wrong
This is an early Phase 2A trial with only 60 participants, so results may not apply to everyone. The drugs may not work better than placebo, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.